Literature DB >> 24877633

Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.

A S L Caldwell1, L J Middleton, M Jimenez, R Desai, A C McMahon, C M Allan, D J Handelsman, K A Walters.   

Abstract

Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, causing a range of reproductive, metabolic and endocrine defects including anovulation, infertility, hyperandrogenism, obesity, hyperinsulinism, and an increased risk of type 2 diabetes and cardiovascular disease. Hyperandrogenism is the most consistent feature of PCOS, but its etiology remains unknown, and ethical and logistic constraints limit definitive experimentation in humans to determine mechanisms involved. In this study, we provide the first comprehensive characterization of reproductive, endocrine, and metabolic PCOS traits in 4 distinct murine models of hyperandrogenism, comprising prenatal dihydrotestosterone (DHT, potent nonaromatizable androgen) treatment during days 16-18 of gestation, or long-term treatment (90 days from 21 days of age) with DHT, dehydroepiandrosterone (DHEA), or letrozole (aromatase inhibitor). Prenatal DHT-treated mature mice exhibited irregular estrous cycles, oligo-ovulation, reduced preantral follicle health, hepatic steatosis, and adipocyte hypertrophy, but lacked overall changes in body-fat composition. Long-term DHT treatment induced polycystic ovaries displaying unhealthy antral follicles (degenerate oocyte and/or > 10% pyknotic granulosa cells), as well as anovulation and acyclicity in mature (16-week-old) females. Long-term DHT also increased body and fat pad weights and induced adipocyte hypertrophy and hypercholesterolemia. Long-term letrozole-treated mice exhibited absent or irregular cycles, oligo-ovulation, polycystic ovaries containing hemorrhagic cysts atypical of PCOS, and displayed no metabolic features of PCOS. Long-term dehydroepiandrosterone treatment produced no PCOS features in mature mice. Our findings reveal that long-term DHT treatment replicated a breadth of ovarian, endocrine, and metabolic features of human PCOS and provides the best mouse model for experimental studies of PCOS pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24877633     DOI: 10.1210/en.2014-1196

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  87 in total

1.  Brown adipose tissue transplantation ameliorates polycystic ovary syndrome.

Authors:  Xiaoxue Yuan; Tao Hu; Han Zhao; Yuanyuan Huang; Rongcai Ye; Jun Lin; Chuanhai Zhang; Hanlin Zhang; Gang Wei; Huiqiao Zhou; Meng Dong; Jun Zhao; Haibin Wang; Qingsong Liu; Hyuek Jong Lee; Wanzhu Jin; Zi-Jiang Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-22       Impact factor: 11.205

2.  Finding the Right Balance: Androgens at the Tipping Point of Fertility and Metabolism in Women.

Authors:  Michael T Sellix; Aritro Sen
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

3.  Neuronal androgen receptor: Molecular gateway to polycystic ovary syndrome?

Authors:  David H Abbott
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-04       Impact factor: 11.205

4.  PCOS: Animal models for PCOS - not the real thing.

Authors:  Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2017-05-05       Impact factor: 43.330

5.  High levels of testosterone inhibit ovarian follicle development by repressing the FSH signaling pathway.

Authors:  Tao Liu; Yu-Qian Cui; Han Zhao; Hong-Bin Liu; Shi-Dou Zhao; Yuan Gao; Xiao-Li Mu; Fei Gao; Zi-Jiang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

6.  Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.

Authors:  Danalea V Skarra; Angelina Hernández-Carretero; Alissa J Rivera; Arya R Anvar; Varykina G Thackray
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

Review 7.  Developmental programming of insulin resistance: are androgens the culprits?

Authors:  Muraly Puttabyatappa; Robert M Sargis; Vasantha Padmanabhan
Journal:  J Endocrinol       Date:  2020-06       Impact factor: 4.286

8.  Low-Dose Dihydrotestosterone Drives Metabolic Dysfunction via Cytosolic and Nuclear Hepatic Androgen Receptor Mechanisms.

Authors:  Stanley Andrisse; Shameka Childress; Yaping Ma; Katelyn Billings; Yi Chen; Ping Xue; Ashley Stewart; Momodou L Sonko; Andrew Wolfe; Sheng Wu
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

9.  Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome.

Authors:  Ling Gao; Jia-Tian Cao; Yan Liang; Yi-Chao Zhao; Xian-Hua Lin; Xiao-Cui Li; Ya-Jing Tan; Jing-Yi Li; Cheng-Liang Zhou; Hai-Yan Xu; Jian-Zhong Sheng; He-Feng Huang
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

10.  Combined androgen excess and Western-style diet accelerates adipose tissue dysfunction in young adult, female nonhuman primates.

Authors:  Oleg Varlamov; Cecily V Bishop; Mithila Handu; Diana Takahashi; Sathya Srinivasan; Ashley White; Charles T Roberts
Journal:  Hum Reprod       Date:  2017-09-01       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.